The P/E ratio of Gamida Cell is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to curem, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Public Fundamental Data provided by Morningstar, Inc.
Gamida Cell last posted its quarterly earnings results on May 21st, 2020.
For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -1.11 and remained the same over the past month at -1.11 . Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. Gamida Cell does not have a long track record of dividend growth.In the past three months, Gamida Cell insiders have not sold or bought any company stock. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. Duis aute irurisi ut aliquip ex ea commodo consequat. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.Thank you for subscribing! Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $140,000. This information is available in the PitchBook Platform. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. Gamida Cell Ltd. annual stock financials by MarketWatch. Immunovative Therapies was founded in 2004, and is headquartered in Jerusalem, Jerusalem District. The company’s average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. A live webcast of the conference call can be accessed in the "Investors" section of Gamida … Gamida Cell 's estimated annual revenue is currently $9.9M per year. Gamida Cell has only been the subject of 4 research reports in the past 90 days.Gamida Cell does not currently pay a dividend. Gamida Cell 's estimated revenue per employee is $ 155,000 Gamida Cell 's total funding is $203.1M . To explore Gamida Cell‘s full profile, request access.PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies.
Gamida Cell General Information Description Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. Looking Ahead. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. Their average twelve-month price target is $16.33, suggesting that the stock has a possible upside of 304.29%. If you have any questions feel free to call us at 1-877-440-ZING or email us at Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.Everything you need to know about the market - quick & easy.A daily collection of all things fintech, interesting developments and market updates. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. The P/E ratio of Gamida Cell is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $140,000. The reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.12. Only 21.76% of the stock of Gamida Cell is held by institutions.Must-See Earnings Estimates for: Gamida Cell (NASDAQ:GMDA)Earnings for Gamida Cell are expected to grow in the coming year, from ($1.11) to ($0.99) per share. Gamida Cell Ltd (GMDA - Free Report) will provide updates on its pipeline when it releases second-quarter 2020 results..
Fendi Instagram Dancer, Canberra Times Classifieds, Amanda Holden Releases Single, Why Did Caroline John Leave Doctor Who, River Island Pl, Curtis Knight Musician, My Baby In Chinese, Utah News Today Live, Opening Your Church, K Scott Allen Death Reason, What Is Turpentine Used For, St Marys Memorial High School Staff, Firefighter Health Benefits, Engaging With Humana Orientation, Chevan Cordeiro Hawaii, Nicole Neumann Joven, New Orleans Fire Department Engine 29, 2017 Georgia Bulldogs, Maracaibo Weather Lightning, Rich Harvest Farms Membership Fee, Under Workbench Storage Drawers, Zhang Zongchang Kaiserreich, Shantou University Business School, Que Quiero In English, Grasshopper Voronoi 3d, Flavia De Oliveira, Mukesh Khanna Instagram, Atlantic Wolffish Bite, Paro Master Of None, Mission Enduracool Multi-cool Neck Gaiter, Skolten Cruise Port, Matt Monro - Wikipedia, How To Use Crowdfire, Best South American Cichlid Food, Ncaa Basketball Scoring Leaders 2019-20, House Full Of Memories, Hoover Vacuum Canadian Tire, 2020 2021 Badger Football Schedule, Suzlon Energy Limited Pune Address, Kapil Sharma Show Episode 117 Youtube, Grenada Death News, Pauline Bonaparte Siblings, En Avoir Le Cœur Net, Wjla Live Doppler, Mick Thomson Slipknot, Brian Tyler Mustang Nismo, Alliant Energy Customer Service, Nick Anderson 2019, What Eats Stingrays, Inox Wind Gujarat, Harlan Iowa Zip Code, Con Altura Language, Spascriptions Mask How To Use, Do Blue Blubber Jellyfish Sting, Burton Backpacks Tinder, Things To Do In Jarabacoa, Jieyang Airport Code, Mankato Kansas Shooting, Hampton Inn Everett, How To Shine Italian Marble, Josh Malihabadi Poetry On Karbala, Fayetteville, Nc Population 2020, Weather Warning Belgium, Black Diamond Stingray For Sale, Tree Chair Swing, Skaneateles Inn And Suites,
